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Pax5/BSAP Maintains the Identity of B Cells
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et al., 1992; Li et al., 1996) suggests an important role
of this transcription factor also at late stages of B lym-
phopoiesis. Such a late function could not, however, be
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studied in Pax5/ mice, due to the complete absenceVienna Biocenter
of B lymphocytes beyond the early pro-B cell stageDr. Bohr-Gasse 7
(Urba´nek et al., 1994). For this reason, the late functionA-1030 Vienna
of Pax5 has only been investigated in immortalized BAustria
cell lines and splenic B cells by Pax5 overexpression
or antisense oligonucleotide interference experiments
(reviewed by Busslinger and Nutt, 1998). These analyses
Summary implicated Pax5 in diverse aspects of late B cell differen-
tiation, including the control of B cell proliferation (Wa-
The B lineage commitment factor Pax5 (BSAP) is ex- katsuki et al., 1994), class switching of the IgH gene
pressed throughout B cell development. To investigate (Liao et al., 1994; Qiu and Stavnezer, 1998), negative
its late function, we generated a mouse strain carrying regulation of immunoglobulin 3 enhancers (Singh and
a floxed Pax5 allele that was conditionally inactivated Birshtein, 1993; Neurath et al., 1994; Roque et al., 1996),
by CD19-cre or Mx-cre expression. Pax5 deletion re- transcriptional repression of the J-chain gene (Rinken-
sulted in the preferential loss of mature B cells, ineffi- berger et al., 1996), and suppression of plasma cell dif-
cient lymphoblast formation, and reduced serum IgG ferentiation (Usui et al., 1997).
levels. Mature B cells radically changed their gene To directly study the late function of Pax5 in vivo, we
expression pattern in response to Pax5 inactivation. have generated a mouse strain containing loxP sites on
Most B cell antigens were downregulated on the cell either side of Pax5 exon 2. This floxed Pax5 allele was
surface, and the transcription of B cell-specific genes conditionally inactivated in vivo by expression of the
B cell-specific CD19-cre (Rickert et al., 1995, 1997) orwas decreased, whereas the expression of non-B
interferon-inducible Mx-cre transgene (Ku¨hn et al.,lymphoid genes was activated in Pax5-deficient B
1995). Here, we demonstrate by flow cytometric andcells. These data demonstrate that Pax5 is essential
molecular analyses that Pax5 plays an essential role infor maintaining the identity and function of B cells
maintaining the identity and function of mature B cellsduring late B lymphopoiesis.
during late B lymphopoiesis.
Introduction
ResultsB lymphocytes develop from hematopoietic stem cells
through intermediate lymphoid progenitors, which undergo
Generation of Mice Carrying a Floxed Pax5 AlleleB lineage commitment and subsequently differentiate
Exon 2 of Pax5 codes for the N-terminal part of thealong the B cell pathway. The developmental progres-
paired domain that is essential for DNA binding of thesion from early pro-B cells to terminally differentiated
transcription factor Pax5 (Czerny et al., 1993). Pre-plasma cells is known to be regulated by a multitude of
viously, we have generated a Pax5 null () allele bytranscription factors. Pax5 (BSAP) is one of the earliest
replacing exon 2 with lacZ sequences (Urba´nek et al.,transcription factors, as B cell development is arrested
1994). To produce a floxed (F) Pax5 allele for Cre-loxP-at the pro-B cell stage in the bone marrow of Pax5
mutant mice (Urba´nek et al., 1994; Nutt et al., 1997). The mediated gene inactivation, we have inserted loxP se-
characterization of Pax5-deficient pro-B cells revealed quences 70 bp upstream and 130 bp downstream of
that these cells are not yet committed to the B lymphoid exon 2 by gene targeting in ES cells (Figure 1A). Hetero-
lineage but instead have a broad lymphomyeloid differ- zygous Pax5F/ mice, derived by blastocyst injection of
entiation potential (Nutt et al., 1999a; Rolink et al., 1999). targeted ES cells (Figure 1B), were crossed with a nestin-
Restoration of Pax5 expression in these progenitors re- cre transgenic line (Betz et al., 1996) to generate Pax5/
stricts, however, the developmental potential to the B mice and with Pax5/ mice to obtain Pax5F/ progeny.
lymphoid pathway, thus identifying Pax5 as an essential Both Pax5F/ and Pax5F/F mice were indistinguishable
B lineage commitment factor (Nutt et al., 1999a). Pax5 from wild-type mice, with regard to normal B cell devel-
exerts its commitment function by activating the expres- opment, behavior, and survival (Figure 1C; data not
sion of B lymphoid-specific genes and by simultane- shown), indicating that the floxed Pax5 allele behaves
ously repressing the transcription of lineage-inappropri- like the wild-type gene. In contrast, Pax5/ mice recapit-
ate genes (Nutt et al., 1997, 1998, 1999a). Hence, the ulated the previously described Pax5 mutant phenotype
suppression of alternative lineage fates seems to criti- (Urba´nek et al., 1994), as demonstrated by their severe
cally depend on the repression function of Pax5, which growth retardation, death at weaning age, and arrest of
is mediated through the interaction with corepressors B cell development at the pro-B cell stage (Figure 1C;
of the Groucho protein family (Eberhard et al., 2000). data not shown). Hence, the deletion of Pax5 exon 2
The continuous expression of Pax5 from the earliest creates a null allele, consistent with the fact that splicing
B lymphoid progenitor to the mature B cell stage (Adams of Pax5 exon 1 sequences to exon 3, 4, or 5 results in
nonfunctional polypeptides due to a shift in reading
frame (Busslinger et al., 1996).1Correspondence: busslinger@nt.imp.univie.ac.at
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Figure 1. Generation of a Conditional Pax5 Allele
(A) Targeted insertion of loxP sequences on both sides of Pax5 exon 2. The targeting vector is shown together with the Pax5 gene structure
surrounding exons 2 and 3. The neomycin (neo) resistance and herpes simplex virus thymidine kinase (tk) genes were flanked by loxP sites
(arrowheads), which allowed deletion of this selection cassette by transient Cre expression prior to injection of the targeted ES cells into
mouse blastocysts. The Pax5 allele was generated by Cre-mediated deletion of exon 2 in the germline of Pax5F/ mice. Correct targeting
was verified by Southern blot analysis of BglII-digested DNA with the indicated probe. The lengths of the respective BglII fragments are shown
in kb. B, BamHI; Bx, BstXI; Bg, BglII.
(B) Germline transmission of the Pax5F allele. Tail DNA from wild-type and Pax5F/ littermates was digested with BglII followed by Southern
blot analysis.
(C) Wild-type function of the Pax5F allele. Bone marrow cells from 2-week-old mice of the indicated genotypes were analyzed by flow cytometry
with FITC-anti-B220 and PE-anti-CD19 antibodies.
Experimental Strategies for Cre-Mediated Deletion preciable deletion of the floxed gene in mice carrying
the Mx-cre transgene under the control of the mouseof Pax5 Exon 2
For conditional inactivation, we have crossed the floxed Mx1 promoter (Ku¨hn et al., 1995). Transcription from the
Mx1 promoter can be transiently induced to high levelsPax5 allele into the CD19-cre and Mx-cre transgenic
lines. The cre recombinase gene under the control of in many different tissues by treatment with type I interfer-
ons (IFN or IFN) or with synthetic double-strandedthe endogenous CD19 locus (Rickert et al., 1995) is spe-
cifically expressed from the pro-B cell to the mature B RNA (polyinosine-polycytosine; pIpC), which efficiently
stimulates endogenous IFN production. The IFN-induc-cell stage (Rickert et al., 1997). Mice hemizygous for
this cre insertion (referred to as CD19-cre mice) are ible expression of the Mx-cre transgene allows simulta-
neous deletion of the floxed gene at all developmentalphenotypically normal, as they still retain one functional
CD19 allele (Rickert et al., 1995). In these mice, the stages, thus facilitating the study of short-term effects
of gene inactivation. However, IFN/ and pIpC alsoCre protein level increases with progression of B cell
development in parallel with CD19 expression (Schwenk have transient antiproliferative and immunomodulatory
functions and are known to interfere with early B cellet al., 1997). Consequently, deletion by CD19-cre is an
ongoing process throughout B lymphopoiesis, which development in the bone marrow (Lin et al., 1998). To
control for these potential side effects, we have studiedresults in a lower deletion efficiency in bone marrow
pre-B cells compared to mature B cells in the spleen the consequence of Pax5 inactivation in Pax5F/ Mx-cre
mice only in comparison with Pax5F/ Mx-cre control(Rickert et al., 1997).
In contrast, B cell development proceeds without ap- littermates, which still retain a wild-type Pax5 allele after
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Cre-mediated deletion. As pIpC proved to be more po-
tent than IFN in inducing Pax5 deletion in vivo, we
inactivated the floxed Pax5 allele in Mx-cre mice by
intraperitoneally injecting pIpC three times at 2 day inter-
vals and then analyzed the lymphoid organs 3 days after
the last injection, as described (Ku¨hn et al., 1995).
Loss of Mature B Cells upon Pax5 Inactivation
We first measured the deletion frequency in splenocytes
of Pax5F/ and Pax5F/ CD19-cre mice by Southern blot
analysis (Figure 2A). Consistent with the B cell-specific
expression of CD19-cre, the floxed Pax5 allele remained
intact in B220 splenocytes, whereas it was deleted in
76% of the B220 B cells of Pax5F/ CD19-cre mice. A
2-fold lower deletion frequency (38%) was observed in
B220 B cells of Pax5F/ CD19-cre mice. Flow cytometric
analyses furthermore demonstrated that the B220
splenocytes were reduced on average 2-fold in Pax5F/
CD19-cre mice compared with Pax5F/ CD19-cre lit-
termates (Figure 2E). We conclude therefore that half of
the splenic B cells were absent due to the Cre-mediated
loss of Pax5 function in Pax5F/ B lymphocytes.
The floxed Pax5 allele was deleted in95% of all liver
cells and B220 splenocytes of pIpC-treated Pax5F/
and Pax5F/ Mx-cre mice (Figure 2B). Similar deletion
frequencies have previously been reported for a floxed
allele of the DNA polymerase  gene (Ku¨hn et al., 1995).
Surprisingly, however, the deletion of the floxed Pax5
allele was less efficient in B220 splenocytes (64%) of
Pax5F/ Mx-cre mice, which may reflect a lower accessi-
bility of the transcriptionally inactive Pax5 allele in mono-
allelically expressing B cells (Nutt et al., 1999b). The
deletion frequency was marginally lower in B220 sple-
nocytes (58%) of Pax5F/ Mx-cre mice (Figure 2B) in agree-
ment with the flow cytometric finding that the B220
splenocytes were only minimally reduced in the spleen
of these mice (Figure 2E). Hence, only a small number
of B cells was lost upon short-term inactivation of Pax5.
The monoclonal antibody 493 recognizes the antigen
AA4 (Petrenko et al., 1999), which is expressed on imma-
ture B lymphocytes in contrast to mature B cells (Rolink
et al., 1998). Flow cytometric analysis of AA4 (493) ex-
pression revealed that the loss of B220 splenocytes in
Pax5F/ CD19-cre mice is primarily caused by a 3-fold
reduction of the long-lived mature 493 B cells (Figures
2C and 2E). In contrast, identical numbers of the short-
lived immature 493 B cells were present in the spleenFigure 2. Loss of Mature B Cells upon Pax5 Inactivation
of both Pax5F/ and Pax5F/ CD19-cre mice. A preferen-(A) Frequency of Pax5 deletion in CD19-cre mice. Splenocytes of
tial loss of mature B cells was also demonstrated byPax5F/ and Pax5F/ CD19-cre mice were MACS sorted as B220 or
B220 cells prior to DNA preparation, BglII digestion, and Southern quantitative PCR analysis of the deletion frequency in
blot analysis. The signals were quantitated by phosphorimager anal- sorted B cell populations. As shown in Figure 2D, the
ysis to calculate the deletion frequency (/[F  ]), which is given deleted Pax5 allele was present at an2-fold lower level
as a percentage below each lane. The characteristic DNA fragment in immature 493 B cells of the Pax5F/ CD19-cre spleen
of each Pax5 allele is indicated by its position and length (in kb).
(B) Pax5 deletion in splenocytes of Mx-cre mice. Three days after
the third pIpC injection, the liver (liv) as well as B220 and B220
splenocytes were analyzed by Southern blot hybridization.
(C) Preferential loss of mature B cells in Pax5F/ CD19-cre mice. ber of B lymphocytes within each cell population is shown as a
Splenocytes from CD19-cre littermates were stained with FITC-anti- percentage of the total cells present in the lymphocyte gate. The
B220 and PE-anti-AA4 (493) antibodies, and the percentages of average number of total splenocytes was 1.7  108 (Pax5F/ CD19-
cells within the indicated gates are shown together with their Pax5 cre), 1.1  108 (Pax5F/ CD19-cre), 1.9  108 (Pax5F/ Mx-cre), and
deletion frequency (to the right). 1.7  108 (Pax5F/ Mx-cre). pIpC treatment of the Mx-cre mice re-
(D) Analysis of Pax5 deletion. Sorted 493B220 and 493B220 sulted in a 3-fold, genotype-independent decrease in short-lived
splenocytes were assayed for deletion of Pax5 exon 2 by quantita- 493B220 cells due to the interferon-induced block of pro-B cell
tive PCR, and the deletion frequency was calculated as described development (Lin et al., 1998). The number of immature B cells in
above. Pax5F/ mice may be slightly overestimated due to the upregulation
(E) Statistical analysis. The splenocytes from mice of the indicated of AA4 (493) expression on mature Pax5-deficient B cells (Figure 5).
genotypes were analyzed by flow cytometry, and the average num- n, number of mice analyzed.
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in the bone marrow of Pax5F/ CD19-cre mice (Figure
3A). This reduction in pre-B cells was apparently caused
by the loss of Pax5, as the deleted allele was underrepre-
sented in sorted IgMB220 (31% versus 52%) and
IgMB220 (57% versus 83%) bone marrow cells of
Pax5F/ CD19-cre mice compared to control littermates
(Figure 3B). In conclusion, these data demonstrate that
Pax5 is essential at all stages of B lymphopoiesis, al-
though the long-lived pool of mature and recirculating
B cells was most dramatically affected by the condi-
tional loss of Pax5 function.
Downregulation of IgD Expression on Mature
B Cells Lacking Pax5 Function
The expression of the mature B cell marker IgD was
specifically downregulated on B cells in the spleen and
lymph nodes of Pax5F/ CD19-cre mice compared to
control littermates (Figures 4B and 4C). This downregu-
lation created a continuum of IgD expression levels on
the surface of these cells, ranging from IgDhi to IgD. In
marked contrast, expression of the surface IgM receptor
remained unaltered on the same mature B cells (Figures
4A and 4B). Moreover, the downregulation of IgD ex-
pression was even prominent on B lymphocytes of pIpC-
treated Pax5F/ Mx-cre mice (Figures 4A and 4C), despite
the fact that the loss of B cells was minimal in these
mice due to short-term inactivation of Pax5 (Figure 2). It
appears therefore that IgD downregulation is a relatively
rapid response to the loss of Pax5 function. Further-
more, PCR analysis of sorted IgDhi and IgDlo/ B cells
demonstrated a direct correlation between the loss of
IgD expression and the deletion of the floxed Pax5 allele
in mature B cells of Pax5F/ CD19-cre mice (Figure 4D).
We conclude therefore that the loss of IgD expression
is a useful surrogate marker for the loss of Pax5 function
Figure 3. Loss of Recirculating B Cells as a Consequence of Pax5 in mature B cells.
Inactivation
(A) Absence of recirculating IgMB220hi B cells in the bone marrow Altered Expression of Surface Proteins on Mature
of Pax5F/ CD19-cre mice. Bone marrow cells from CD19-cre lit- Pax5-Deficient B Cells
termates of the indicated genotypes were analyzed by flow cytome- Immature B cells of the spleen also express low IgD
try with FITC-anti-B220 and PE-anti-IgM antibodies. The percentage
levels and could therefore be mistaken as mature B cellsof cells in each gate is indicated together with the frequency of
that have downregulated IgD expression in response toPax5 deletion (shown to the right).
Pax5 inactivation. However, the level of IgM expression(B) Pax5 deletion in bone marrow B lymphocytes. The Pax5 deletion
could be used to discriminate the immature IgMhi B cellsfrequency in sorted IgMB220 and IgMB220 cells from the bone
marrow of CD19-cre littermates was analyzed by quantitative PCR from the mature IgMlo B cells, even in Pax5F/ CD19-cre
as described in Figure 2D. mice, as the expression of IgM is unaltered on Pax5-
(C) Absence of IgDB220hi B cells in the bone marrow of Pax5F/ mice deficient splenic B cells (Figures 4A and 5A). We there-
carrying the CD19-cre or Mx-cre transgene. The Mx-cre littermates fore stained splenocytes of Pax5F/ CD19-cre mice with
were injected only once with pIpC prior to flow cytometric analysis anti-IgD and anti-IgM antibodies in combination with an
with FITC-anti-B220 and PE-anti-IgD antibodies.
antibody recognizing a third B cell surface protein (Fig-
ure 5B). As the downregulation of IgD expression pro-
gresses with increasing time after Pax5 deletion (Figure(38%) compared to control littermates (63%), indicating
that Pax5-deficient B lymphocytes contribute less effi- 4D), we gated on IgDhiIgMlo, IgDloIgMlo, and IgDIgMlo
splenocytes (Figure 5A) and displayed the expressionciently to the immature B cell pool. More conspicuously,
the deleted Pax5 allele was 5-fold underrepresented in of the third B cell marker on these cell fractions (Figure
5B). For comparison, expression of the same B cell pro-mature 493 B cells (16%) of the Pax5F/ CD19-cre
spleen compared to control mice (79%). Hence, we con- teins was also analyzed on mature IgDhiIgMlo spleno-
cytes of control Pax5F/CD19-cre littermates. In additionclude that mature B cells lacking Pax5 function are pref-
erentially lost. to IgM, the expression of B220, CD38, and CD44 was
largely unaltered on B cells lacking Pax5 function. Sur-The loss of the mature B cells in the periphery resulted
in the absence of recirculating IgMIgDB220hi cells in prisingly, however, seven B cell markers (CD19, CD21,
CD22, CD23, CD40, CD72, and MHC class II) behavedthe bone marrow of Pax5F/ CD19-cre mice compared to
control littermates (Figures 3A and 3C). The IgDB220hi like IgD, as their expression was consistently downregu-
lated on Pax5-deficient B cells, although to varying de-cells were even absent in the bone marrow of pIpC-
treated Pax5F/ Mx-cre mice (Figure 3C). In addition, the grees. The differential loss of expression could reflect
differences in the half-life and/or internalization rate ofshort-lived IgMB220lo pre-B cells and the IgMB220lo
immature B cells were present at slightly lower numbers the individual proteins. Importantly, the expression of
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Figure 4. Downregulation of IgD Expression on Mature Pax5-Deficient B Cells
(A and B) Downregulation of IgD expression on B lymphocytes in the spleen (A) and lymph nodes (B) of Pax5F/ mice expressing the CD19-
cre or Mx-cre transgene. CD19-cre mice and pIpC-treated Mx-cre littermates of the Pax5F/ and Pax5F/ genotypes were stained with FITC-
anti-IgM and PE-anti-IgD antibodies, and the percentages of cells within the indicated gates are shown.
(C) Statistical analysis. The splenocytes and lymph node cells from mice of the indicated genotypes were analyzed by flow cytometry, and
the average number of B lymphocytes within each cell population is shown as a percentage of the total cells present in the lymphocyte gate.
(D) Correlation between IgD loss and Pax5 gene deletion. Splenocytes of CD19-cre mice were sorted into IgDhiB220 and IgDlo/B220 cells
prior to quantitative PCR analysis of the Pax5 deletion frequency as described in Figure 2D.
three proteins, AA4 (493), CD25 (IL-2R), and CD138 a marker of immature B lymphocytes (Rolink et al., 1998).
As shown in Figure 7B, expression of the AA4 (493) protein(syndecan-1), was efficiently induced on all Pax5-defi-
cient B cells. Moreover, expression of the activation could be activated by lipopolysaccharide (LPS) treatment
on mature splenic B cells of control mice, indicating thatmarkers CD69 and CD86 was only weakly increased,
the cell size did not change, and CD95 (Fas) was not the AA4 (493) protein is reexpressed on plasmablasts simi-
lar to CD25 and CD138 (Sanderson et al., 1989). At faceupregulated upon Pax5 deletion (Figure 5B; data not
shown). These latter observations therefore failed to value, it would appear therefore that many of the expres-
sion changes initiated by Pax5 inactivation seem to corre-reveal any overt sign of B cell activation or apoptosis
in the mature Pax5-deficient B cells analyzed. late with alterations normally seen upon plasma cell differ-
entiation (Manz et al., 1998; McHeyzer-Williams et al.,The immature IgDloIgMhi493 B lymphocytes (Rolink
et al., 1998) and the marginal zone B cells with their 2000). However, it is equally conceivable that Pax5 inacti-
vation leads to the loss of B cell identity and to concomitantcharacteristic IgDloIgMhiCD21hiCD23lo phenotype (Oliver
et al., 1997a) could potentially contribute to the observed activation of genes from other hematopoietic lineage
programs. Flow cytometric analysis failed, however, toexpression changes in the spleen of Pax5F/ CD19-cre
mice by contaminating the IgDlo/ cell fraction. Both im- detect the expression of markers of other hematopoietic
lineages on Pax5-deficient B cells from Pax5F/ CD19-mature B lymphocytes and marginal zone B cells are,
however, absent in the lymph node (Oliver et al., 1997a). cre lymph nodes (Figure 5E).
We therefore reinvestigated the expression of some of
the B cell markers on lymph node cells of Pax5F/ CD19-
cre mice (Figures 5C and 5D). This analysis unequivo- Loss of B Lymphoid Gene Expression in Mature
Pax5-Deficient B Cellscally demonstrated that the observed cell surface
changes were caused by the loss of Pax5 function rather The observation that mature B lymphocytes express
CD25 only upon Pax5 inactivation identified CD25 asthan by contaminating B lymphocytes. The induction of
AA4 (493) expression on mature Pax5-deficient B cells an ideal marker for positive selection of mature Pax5-
deficient B cells (Figure 6A). Semiquantitative RT-PCRwas surprising, as this protein was so far described as
Immunity
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Figure 5. Pax5 Inactivation Alters the Cell Surface Phenotype of Mature B Cells
Cells isolated from the spleen (A and B) or lymph nodes (C–E) of Pax5F/ and Pax5F/ CD19-cre littermates were stained with Alexa488-anti-
IgM and APC-anti-IgD antibodies in combination with a third PE-labeled antibody. The stained cells of the spleen (A) and lymph nodes (C)
were gated into IgDhi, IgDlo, and IgD B cells as indicated. The staining of these cell fractions by the third antibody is displayed in (B) (spleen),
(D), and (E) (lymph node), respectively. One representative staining of seven different experiments is shown. Only live cells were analyzed, as
apoptotic or necrotic cells were excluded by propidium iodide staining.
Pax5 Is Essential for Late B Cell Development
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Figure 6. Gene Expression Changes in Ma-
ture Pax5-Deficient B Cells
(A) CD25 as a marker for positive selection
of Pax5-deficient B cells. Cells from the lymph
nodes of Pax5F/ and Pax5F/ CD19-cre lit-
termates were stained with Alexa488-anti-
IgM and PE-anti-CD25 antibodies. The indi-
cated gates were used to sort B cells for
RT-PCR analysis.
(B) Semiquantitative RT-PCR. Transcripts of
the indicated genes were quantitated by RT-
PCR in sorted CD25IgM and CD25IgM
cells from lymph nodes of two Pax5F/ CD19-
cre mice, and the PCR products were visual-
ized on agarose gels by ethidium bromide
staining. Pax5 transcripts were amplified ei-
ther from exon 1A to 5 (5) or from exon 6 to
10 (3). “FL” denotes the full-length transcript
of the Pax5F allele, and “E2” denotes the
Pax5 transcript lacking exon 2. Expression
of the two derepressed genes was very low
(CD138) or undetectable (M-CSF-R) in mature
B cells of wild-type mice (data not shown). In
contrast, these mRNAs were present at detect-
able levels in CD25IgM cells of Pax5F/
CD19-cre mice, due to partial derepression
as a consequence of the observed deletion
of the Pax5F allele in a subset of these cells.
analysis was therefore used to study the gene expres- creased in CD25 B cells compared to CD25 B cells.
The second group consisted of mRNAs displaying a lesssion changes in sorted CD25IgM and CD25IgM B
cells from lymph nodes of Pax5F/ CD19-cre mice (Figure severe or only minimal reduction upon Pax5 loss. Genes
of this category code for the cell surface proteins Ig	m6B). As expected, the CD25 B cells had undergone
deletion of the floxed Pax5 allele and consequently ex- and Ig (B29), the Syk kinase, the J chain, and the tran-
scription factors EBF, E47, Ikaros, and Blimp-1. Finally,pressed a truncated Pax5 transcript lacking exon 2. In
contrast, the majority of the CD25 B cells still expressed the CD138 and M-CSF-R transcripts characterized the
third class of genes, which were activated in responsethe full-length Pax5 mRNA. The truncated Pax5 tran-
script was, however, already present in a significant to Pax5 deletion.
The following conclusions can be drawn from theseproportion of the CD25 B cells, thus indicating that
there is a delay between the loss of functional Pax5 expression data. First, there is a good correlation be-
tween cell surface protein and mRNA expression ofmRNA and the expression of CD25 on the cell surface.
PCR amplification of common 3 sequences furthermore those genes, which were studied by flow cytometry (Fig-
ures 5B and 5D) as well as RT-PCR analysis (Figuredemonstrated that the level of total Pax5 mRNA re-
mained unchanged in both the CD25 and CD25 B 6B). CD19 and Ig
m expression was downregulated, and
CD138 was upregulated in Pax5-deficient B cells,cell populations similar to the expression of the control
HPRT gene. whereas the expression of Ig	m was minimally affected
both at the mRNA and protein level. Second, the majorityThe different genes analyzed could be grouped into
three categories according to their expression changes of all B cell-specific transcripts was decreased in Pax5-
deficient B cells, consistent with the observed downreg-in response to Pax5 inactivation (Figure 6B). The tran-
scripts coding for the cell surface proteins CD19, Ig
m, ulation of most B cell surface proteins, and at least
one myeloid gene (M-CSF-R) was induced upon Pax5and Ig (mb-1), the signal transducer BLNK (SLP-65),
and the transcription factor CIITA were strongly de- inactivation. This evidence further demonstrates that
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Figure 7. Reduced IgG Secretion and Plas-
mablast Formation of Pax5-Deficient B Cells
(A) Reduced IgG levels in the serum of Pax5F/
CD19-cre mice. The serum immunoglobulin
levels of unchallenged CD19-cre littermates
were analyzed by ELISA. Total immunoglob-
ulin was determined with Ig-specific anti-
bodies. Note that immunization of Pax5F/
CD19-cre mice with T cell-dependent and -in-
dependent antigens resulted in normal IgM
and IgG responses, due to the presence of a
significant proportion of B cells, which had
not yet undergone Pax5 deletion and could
thus participate in the germinal center reac-
tion and plasma cell differentiation (data not
shown).
(B) Kinetics of LPS-induced activation of
splenic B cells. Splenocytes of Pax5F/ CD19-
cre mice were left untreated (0 hr) or stimu-
lated with LPS (50 	g/ml) for 6, 24, and 48 hr
prior to staining with FITC-anti-B220 and PE-
anti-IgD or PE-anti-AA4 (493) antibodies. The
forward scatter (FSC) profile and antibody
staining of the B220 B cells are shown.
(C) Inefficient lymphoblast formation of Pax5-
deficient B cells. Lymph node cells from
Pax5F/ and Pax5F/ CD19-cre littermates
were stimulated with LPS (20 	g/ml) for 0, 12,
and 24 hr prior to staining with Alexa488-anti-
IgM, APC-anti-IgD, and PE-anti-CD86 anti-
bodies. IgDhiIgM and IgDlo/IgM B cells
were gated as indicated in Figure 5C, and the
CD86 expression pattern and FSC profile are
shown for the gated cell populations.
mature B lymphocytes lose their B cell identity in re- This reduction in serum immunoglobulin was entirely
caused by a decrease in IgG synthesis, while the IgMsponse to Pax5 loss. Finally, the expression of the
plasma cell-specific Blimp-1 and J-chain genes was not and IgA levels remained unchanged (Figure 7A). Further-
more, the expression of all four IgG isotypes was differ-induced in Pax5-deficient B cells. Hence, the loss of
Pax5 does not seem to activate the terminal differentia- entially affected in Pax5F/ CD19-cre mice, ranging from
a 9.4-fold reduction of IgG1 to a 2-fold decrease of IgG3tion program, despite its induction of the plasma cell
marker CD138. (Figure 7A). These data further demonstrate that the
loss of Pax5 function does not promote plasma cell
differentiation. Instead, Pax5 seems to be required forInefficient Lymphoblast Formation and IgG
efficient class switching or expression of the differentSecretion in Pax5F/ CD19-cre Mice
IgG isotypes.To independently investigate a possible link between
As cell division is a prerequisite for class switchingPax5 inactivation and plasma cell differentiation, we
(Lundgren et al., 1995; Hodgkin et al., 1996), we nextcompared the serum immunoglobulin levels in unchal-
investigated the LPS-induced proliferation response oflenged Pax5F/ and Pax5F/ CD19-cre mice by quantita-
mature Pax5-deficient B cells. Since LPS treatment istive ELISA. As shown in Figure 7A, the concentration of
known to lead to downregulation of IgD expression ontotal immunoglobulin was 3-fold reduced in the serum of
Pax5F/ CD19-cre mice compared to control littermates. mature B cells (Monroe et al., 1983), we first analyzed
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the kinetics of LPS activation in B cells of control mice mRNA splicing or in the suppression of transcription
termination downstream of the c	 gene.(Figure 7B). Upon LPS addition, the small resting B cells
Pax5 was previously shown to directly regulate theof the spleen differentiate into proliferating lymphoblasts,
transcription of CD19 (Nutt et al., 1998), mb-1 (Ig) (Nuttwhich continuously increase their cell size during the
et al., 1998), and BLNK (M. Schebesta, P. Pfeffer, andnext 48 hr (Figure 7B). The expression of IgD was even
M.B., unpublished data) at the pro-B cell stage of Bslightly augmented during the first 24 hr but thereafter
lymphoid development. In mature B cells, the transcrip-started to decline to low levels at 48 hr (Figure 7B).
tion of these three genes was also lost upon Pax5 inacti-Hence, the loss of IgD expression could be reliably used
vation, indicating that their expression is under the directto identify Pax5-deficient B cells only within the first 24
control of Pax5 throughout B cell development. Pax5hr of LPS stimulation. Lymph node cells from Pax5F/
has additionally been implicated in the regulation of theand Pax5F/ CD19-cre littermates were therefore stimu-
CD72 gene (Ying et al., 1998), whose expression waslated for 12 and 24 hr with LPS, and the activation marker
also decreased in mature Pax5-deficient B cells. At pres-CD86 was shown by flow cytometry to be similarly in-
ent, there is no information available about a possibleduced on IgDhiIgM (Pax5) and IgDlo/IgM (Pax5) B
role of Pax5 in the regulation of all other genes, whichcells of Pax5F/ CD19-cre mice (Figure 7C). Moreover, the
were affected by the loss of Pax5 in mature B cells.increase in cell size and hence the extent of lymphoblast
It is therefore conceivable that Pax5 is only indirectlyformation was identical in LPS-treated IgDhiIgM B cells
involved in the control of the majority of these genes.of both genotypes. In contrast, the IgDlo/IgM B cells
In this regard, the Pax5-dependent decrease of MHCof Pax5F/ CD19-cre mice were able to increase their
class II gene expression is an illustrative example. Thecell size only with low efficiency and considerable delay
transcription of this gene family is known to criticallyfollowing LPS exposure (Figure 7C). Hence, the reduced
depend on the transactivator CIITA (Steimle et al., 1993),lymphoblast potential of Pax5-deficient B cells could
whose expression was efficiently downregulated in ma-explain the decreased IgG class switching in Pax5F/
ture B cells in response to Pax5 inactivation. Hence, itCD19-cre mice.
is likely that Pax5 mediates its effect on MHC class II
gene expression indirectly by activating the transcrip-Discussion tion of the CIITA gene.
The conditional inactivation of Pax5 in CD19-cre mice
The continuous expression of Pax5 throughout B lym- led to a preferential loss of mature B cells in peripheral
phopoiesis has implicated this transcription factor in lymphoid organs and to the absence of recirculating B
both early and late processes of B cell development cells in the bone marrow, consistent with the observa-
(Busslinger and Nutt, 1998). Conventional gene targeting tion that the expression and recombinase activity of
uncovered the early function of Pax5 (Urba´nek et al., CD19-cre are highest at late stages of B cell develop-
1994), which is required for commitment of lymphoid ment (Schwenk et al., 1997; Rickert et al., 1997). This
progenitors to the B cell pathway (Nutt et al., 1999a; decrease in cell viability could be caused by the absence
Rolink et al., 1999). Here, we have demonstrated by of a survival signal emanating from the B cell receptor
conditional mutagenesis that Pax5 is also essential at (BCR) (Lam et al., 1997). However, the loss of Pax5
late developmental stages to maintain the function, function did not directly alter the expression of IgM on
identity, and survival of mature B lymphocytes. mature B cells, although it may interfere with intracellular
The phenotypic analysis of conditionally inactivated signaling downstream of this receptor. In support of
B lymphocytes was complicated by the relatively ineffi- this idea, the mRNA coding for the signal-transducing
cient deletion of the floxed Pax5 allele by the CD19-cre component Ig (mb-1) of the BCR was strongly de-
and Mx-cre transgenes. As a consequence, the periph- creased in Pax5-deficient B cells, and, as a conse-
eral B lymphocytes were constantly replenished and quence, Ig may become rate limiting for BCR signaling
diluted with nondeleted immature B cells from the bone with progressing time after Pax5 deletion. Moreover, the
marrow. Positive identification of the Pax5-deficient B BLNK (SLP-65) gene, which was also efficiently down-
lymphocytes was therefore a prerequisite for their fur- regulated upon Pax5 inactivation, is known to code for
ther characterization. To this end, we identified the down- a B cell-restricted adaptor molecule playing a central
regulation of surface IgD expression as a surrogate role in BCR signaling (Fu et al., 1998; Wienands et al.,
marker for the loss of Pax5 function in mature B cells. 1998). Mutant mice lacking either BLNK (Jumaa et al.,
Intriguingly, however, IgM expression was maintained 1999; Hayashi et al., 2000) or the cytoplasmic tail of
on the same Pax5-deficient B cells. This differential pro- Ig (Torres et al., 1996) display a characteristic loss of
tein expression was also reflected at the mRNA level, mature B lymphocytes in the spleen and of recirculating
as the Ig
m transcript was lost in Pax5-deficient B cells B cells in the bone marrow. It is therefore likely that the
in contrast to the Ig	m mRNA. Two distinct processes combined loss of BLNK and Ig (mb-1) expression is
are known to control the relative expression of Ig	 and responsible for the reduced viability of mature Pax5-
Ig
 mRNA, both of which are expressed from the same deficient B cells.
rearranged transcription unit of the IgH locus (Cheng et A critical role of Pax5 in the control of B cell prolifera-
al., 1982). In mature B cells, the two mRNAs are derived tion was indicated by the finding that mature Pax5-defi-
from a common precursor RNA by alternative splicing cient B cells have a reduced potential to undergo
(Mather et al., 1984). In contrast, transcription of the lymphoblast formation in response to LPS treatment. A
IgH gene is abruptly terminated between the c	 and c
 similar conclusion was previously reached on the basis
exons in response to antigen stimulation, thus resulting of antisense oligonucleotide interference data (Waka-
in the specific loss of Ig
 mRNA in activated B cells tsuki et al., 1994). Interestingly, the B lymphocytes of
(Mather et al., 1984). The loss of Ig
m mRNA in mature BLNK-deficient mice also show reduced proliferative
Pax5-deficient B cells suggests therefore that Pax5 is responses to B cell mitogens including LPS (Jumaa et
al., 1999; Hayashi et al., 2000). Hence, a signaling defectinvolved either in positive regulation of alternative Ig
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(15 	g) was electroporated into E14.1 ES cells (1  107) followeddue to the loss of BLNK expression is likely responsible
by selection with 150 	g/ml of bioactive G418. Individual clonesfor the reduced proliferation potential of Pax5-deficient
were screened for homologous recombination by nested PCR, andB cells. A defect in B cell proliferation may also explain
positive clones were verified by Southern blot analysis of BglII-the decreased serum IgG levels in Pax5F/ CD19-cre
digested DNA with a previously described EcoRI-ApaI DNA probe
mice, as cell division is a prerequisite for IgH class (Urba´nek et al., 1994). The cells (1  107) of 1 of 11 positive ES
switching to occur in the B cell follicles of the spleen cell clones were electroporated with pMC-cre (3 	g) followed by
(Lundgren et al., 1995; Hodgkin et al., 1996). The prolifer- selection with 2 	M gancyclovir. Two ES cell clones with correct
ation defect of Pax5-deficient B cells therefore pre- deletion of the selection cassette were injected into C57BL/6 blasto-
cysts, and chimeric males were mated with C57BL/6 females tocluded a direct assessment of the in vivo role of Pax5
obtain Pax5F/ offspring.in class switching, although Pax5 has been implicated
in the regulation of germline  transcription in in vitro
Genotypingcultured B cells (Liao et al., 1994; Qiu and Stavnezer,
The Pax5F/ and Pax5F/ mice were maintained on the C57BL/6x129/1998).
Sv background and genotyped by PCR with the following primers:The loss of Pax5 expression takes place as a normal
5-AGGAGCTCCTGGTGGCTCAGCTGA-3 (Pax5 primer 1), 5-CCAphysiological process during the differentiation of ma-
CAGCTACTTTGAATAGGGTGAT-3 (Pax5 primer 2), and 5-TTGA
ture B cells to immunoglobulin-secreting plasma cells CCGTAATGGGATAGGTTACG-3 (lacZ). The wild-type (), lacZ
(Adams et al., 1992), which are characterized by the knockin (), floxed (F), and deleted () Pax5 alleles gave rise to PCR
following cell surface phenotype: CD19loCD21CD22 products of 578, 672, 765, and 267 bp, respectively. The following
CD23CD38loCD40loCD44hiCD72CD138hiMHCIIloIgD oligonucleotides were used for PCR genotyping of the CD19-cre
mouse (Rickert et al., 1995): 5-CTATCTGAAAAATATTTAACAGGTIgMB220lo (Oliver et al., 1997b; Manz et al., 1998; Ying et
GCCAC-3 (CD19 5), 5-CACTATCCTCCACGTTCACTGTCCA-3al., 1998; McHeyzer-Williams et al., 2000; M.G. McHey-
(CD19 3), and 5-GGCAAATTTTGGTGTACGGTCAGTAA-3 (cre).zer-Williams and R. Manz, personal communication). In-
PCR fragments of 700 and 950 bp were indicative of the cre knockinterestingly, the conditional Pax5 loss in mature B cells
and wild-type CD19 alleles, respectively. The Mx-cre transgenicelicited pleiotropic expression changes, which resemble
mice (Ku¨hn et al., 1995) were genotyped with the cre-specific prim-
those observed upon plasma cell differentiation. Most ers 5-CAATTTACTGACCGTACAC-3 and 5-TAATCGCCATCTTC
B cell markers (CD19, CD21, CD22, CD23, CD40, CD72, CAGCAG-3, resulting in a 1 kb PCR product.
MHCII, IgD) were downregulated on the cell surface of
mature Pax5-deficient B cells, whereas the expression Mx-cre Activation
of proteins [CD25, CD138, AA4 (493)] associated with B Double-stranded poly(I)-poly(C) RNA (pIpC; Pharmacia, Uppsala,
Sweden) was dissolved at 1 mg/ml in PBS. Mx-cre mice were in-cell activation and plasma cell differentiation was in-
jected intraperitoneally with 400 	g of pIpC each on day 0, 2, andduced. Despite this impressive correlation with the
4, and the spleen and lymph nodes were analyzed on day 7. Boneplasma cell phenotype, the loss of Pax5 alone was not
marrow cells were analyzed 3 days after a single pIpC injection.sufficient to activate the terminal differentiation program
for the following reasons. First, the expression of IgM,
PCR Analysis of the Deletion FrequencyCD38, and B220 remained high on mature Pax5-defi-
Spleen and bone marrow cells were stained with FITC-anti-B220
cient B cells in contrast to plasma cells. Second, Pax5 and BI-anti-AA4 (493) or FITC-anti-B220 and BI-anti-IgM antibodies
inactivation did not lead to an increase in cell size char- followed by incubation with PE-streptavidin. 493, 493, IgM, and
acteristic of plasma cells (McHeyzer-Williams et al., IgM B220-positive B lymphocytes were sorted with a FACSVantage
2000). Third, the immunoglobulin levels were decreased TSO flow-cytometer (Becton-Dickinson) into fetal calf serum, fol-
lowed by centrifugation and proteinase K digestion. DNA corre-rather than increased in the serum of Pax5F/ CD19-cre
sponding to 20,000 sorted cells was subjected to 20 cycles (linearmice. Last but not least, the loss of Pax5 failed to acti-
range) of PCR amplification with the Pax5 primer pair 1/2 (see above)vate the plasma cell-specific J-chain and Blimp-1 genes
followed by Southern blot analysis with a 267 bp DNA probe ampli-above their basal expression level in mature B cells,
fied from the Pax5 allele.although Blimp-1 is known to be a key regulator of the
plasma cell differentiation program (Turner et al., 1994).
RT-PCR Analysis
In contrast, the myeloid M-CSF-R gene was induced in Lymph node cells from Pax5F/ CD19-cre mice were stained with
mature B cells upon Pax5 inactivation in analogy to its PE-anti-CD25 and Alexa488-anti-IgM antibodies. CD25IgM and
expression in Pax5/ pro-B cells (Nutt et al., 1999a). CD25IgM cells (2 105) were sorted into PBS containing 2% FCS,
Taken together, the lineage-promiscuous M-CSF-R ex- centrifuged, and dissolved in Trizol (300 	l), followed by the addition
of E. coli tRNA (5 	g) and RNA isolation. Reverse transcription (withpression and the downregulation of multiple B cell-spe-
random hexamer primers), RNase H digestion, and PCR amplifica-cific genes in Pax5-deficient B cells unequivocally dem-
tion were performed as described (Nutt et al., 1999b). The PCRonstrate that Pax5 is essential for maintaining the
products were separated on agarose gels and visualized by ethidiumidentity and function of mature B cells. Hence, Pax5
bromide staining. The primer sequences and details of the RT-PCRconfers B lymphoid identity not only at B lineage com-
analysis are available on request (busslinger@nt.imp.univie.ac.at).
mitment (Nutt et al., 1999a; Rolink et al., 1999) but also The Pax5(5), Ig	m, Ig
m, CIITA, and Syk cDNAs were amplified by
at late stages of B cell development. 25 PCR cycles, whereas 30 cycles were used for all other transcripts
except for the E47 cDNA (35 cycles).
Experimental Procedures
Antibodies and Flow Cytometry
The following monoclonal antibodies were purified and conjugatedGeneration of Pax5F Mutant Mice
The Pax5 targeting vector was assembled in a pSP64 plasmid con- with sulfo-NHS-biotin (Pierce Chemical Company, Rockford, IL),
Alexa488 (Molecular Probes, Eugene, OR), or allophycocyanin (APC;taining a polylinker with appropriate loxP and restriction sites. A 1.6
kb NotI-BamHI fragment (intron 1) and 4.8 kb HindIII-BstXI fragment ProZyme, San Leandro, CA) according to the supplier’s instruction:
anti-CD19 (1D3), CD40 (FGK45.5), IgM (M41.42), IgD (1.19), MHC(intron 2) of pGNA-Pax5 (Urba´nek et al., 1994) were inserted as
homology arms together with a 400 bp PCR fragment of exon 2 class II (M5-114), and AA4 (493) antibodies. All other reagents were
obtained from PharMingen (San Diego, CA) as biotin (BI)-, fluores-and a floxed selection cassette containing the HSV-tk (negative
selection) and tk-neo (positive selection) genes. NotI-linearized DNA cein isothiocyanate (FITC)-, or phycoerythrin (PE)-coupled antibod-
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ies: anti-B220 (RA3-6B2), CD3 (145-2C11), CD11c (HL3), CD22 Ku¨hn, R., Schwenk, F., Aguet, M., and Rajewsky, K. (1995). Inducible
gene targeting in mice. Science 269, 1427–1429.(Cy34.1), CD23 (B3B4), CD25 (PC61), CD38 (90), CD43 (S7), CD44
(IM7), CD72 (10-1.D.2), CD86 (GL1), CD95 (Jo2), and CD138 (281- Lam, K.-P., Ku¨hn, R., and Rajewsky, K. (1997). In vivo ablation of
2), Gr-1 (RB6-8C5), Mac-1 (M1/70), NK1.1 (PK136), Thy1.2 (53-2.1), surface immunoglobulin on mature B cells by inducible gene tar-
and Ter119 (TER-119) antibodies. The PE-anti-CD21 (7G6) antibody geting results in rapid cell death. Cell 90, 1073–1083.
was obtained from J. Kearney (Birmingham, AL). Only mice at the Li, Y.-S., Wasserman, R., Hayakawa, K., and Hardy, R.R. (1996).
age of 2 months were analyzed by flow cytometry. Single-cell Identification of the earliest B lineage stage in mouse bone marrow.
suspensions were stained with the respective antibodies and ana- Immunity 5, 527–535.
lyzed on a FACSCalibur flow-cytometer (Becton Dickinson) as de-
Liao, F., Birshtein, B.K., Busslinger, M., and Rothman, P. (1994). Thescribed (Urba´nek et al., 1994). Unspecific antibody binding was
transcription factor BSAP (NF-HB) is essential for immunoglobulinsuppressed by the preincubation of cells with CD16/CD32 Fc-block
germ-line  transcription. J. Immunol. 152, 2904–2911.solution (PharMingen). Biotinylated antibodies were revealed by in-
Lin, Q., Dong, C., and Cooper, M.D. (1998). Impairment of T and Bcubation with PE- or APC-labeled streptavidin (Southern Biotech-
cell development by treatment with a type I interferon. J. Exp. Med.nology Associates or PharMingen, respectively).
187, 79–87.
Serum Immunoglobulin Measurements Lundgren, M., Stro¨m, L., Bergquist, L.-O., Skog, S., Heiden, T., Stav-
The concentrations of the different immunoglobulins were measured nezer, J., and Severinson, E. (1995). Cell cycle regulation of immuno-
in the serum of at least 8-week-old mice by enzyme-linked immuno- globulin class switch recombination and germ-line transcription:
sorbent assay (ELISA) as described (Urba´nek et al., 1994). potential role of Ets family members. Eur. J. Immunol. 25, 2042–2051.
Manz, R.A., Lo¨hning, M., Cassese, G., Thiel, A., and Radbruch, A.
Acknowledgments (1998). Survival of long-lived plasma cells is independent of antigen.
Int. Immunol. 10, 1703–1711.
We thank K. Rajewsky for providing Mx-cre and CD19-cre mice; H. Mather, E.L., Nelson, K.J., Haimovich, J., and Perry, R.P. (1984).
Cremer for the E14.1 ES cells; P. Steinlein and K. Paiha for FACS Mode of regulation of immunoglobulin 	- and 
-chain expression
sorting; Z.-Q. Wang for blastocyst injection; A. Rolink and J. Kearney varies during B-lymphocyte maturation. Cell 36, 329–338.
for antibodies; and G. Schaffner for DNA sequencing. This research
McHeyzer-Williams, L.J., Cool, M., and McHeyzer-Williams, M.G.was supported by Boehringer Ingelheim and in part by the Austrian
(2000). Antigen-specific B cell memory: expression and replen-Industrial Research Promotion Fund.
ishment of a novel B220- memory B cell compartment. J. Exp. Med.
191, 1149–1165.Received July 12, 2000; revised April 26, 2001.
Monroe, J.G., Havran, W.L., and Cambier, J.C. (1983). B lymphocyte
activation: entry into cell cycle is accompanied by decreased ex-References
pression of IgD but not IgM. Eur. J. Immunol. 13, 208–213.
Neurath, M.F., Strober, W., and Wakatsuki, Y. (1994). The murine IgAdams, B., Do¨rfler, P., Aguzzi, A., Kozmik, Z., Urba´nek, P., Maurer-
3 enhancer is a target site with repressor function for the B cellFogy, I., and Busslinger, M. (1992). Pax-5 encodes the transcription
lineage-specific transcription factor BSAP (NF-HB, S-BP). J. Immu-factor BSAP and is expressed in B lymphocytes, the developing
nol. 153, 730–742.CNS, and adult testis. Genes Dev. 6, 1589–1607.
Nutt, S.L., Urba´nek, P., Rolink, A., and Busslinger, M. (1997). Essen-Betz, U.A.K., Vohenrich, C.A.J., Rajewsky, K., and Mu¨ller, W. (1996).
tial functions of Pax5 (BSAP) in pro-B cell development: differenceBypass of lethality with mosaic mice generated by Cre-loxP-medi-
between fetal and adult B lymphopoiesis and reduced V-to-DJ re-ated recombination. Curr. Biol. 6, 1307–1316.
combination at the IgH locus. Genes Dev. 11, 476–491.Busslinger, M., and Nutt, S.L. (1998). Role of the transcription factor
Nutt, S.L., Morrison, A.M., Do¨rfler, P., Rolink, A., and Busslinger, M.BSAP (Pax-5) in B-cell development. In Molecular Biology of B-Cell
(1998). Identification of BSAP (Pax-5) target genes in early B-celland T-Cell Development, J.G. Monroe and E.V. Rothenberg, eds.
development by loss- and gain-of-function experiments. EMBO J.(Totowa, NJ: Humana Press, Inc.), pp. 83–110.
17, 2319–2333.Busslinger, M., Klix, N., Pfeffer, P., Graninger, P.G., and Kozmik, Z.
Nutt, S.L., Heavey, B., Rolink, A.G., and Busslinger, M. (1999a).(1996). Deregulation of PAX-5 by translocation of the E	 enhancer
Commitment to the B-lymphoid lineage depends on the transcrip-of the IgH locus adjacent to two alternative PAX-5 promoters in a
tion factor Pax5. Nature 401, 556–562.diffuse large-cell lymphoma. Proc. Natl. Acad. Sci. USA 93, 6129–
6134. Nutt, S.L., Vambrie, S., Steinlein, P., Kozmik, Z., Rolink, A., Weith,
A., and Busslinger, M. (1999b). Independent regulation of the twoCheng, H.-L., Blattner, F.R., Fitzmaurice, L., Mushinski, J.F., and
Pax5 alleles during B-cell development. Nature Genet. 21, 390–395.Tucker, P.W. (1982). Structure of genes for membrane and secreted
murine IgD heavy chains. Nature 296, 410–415. Oliver, A.M., Martin, F., Gartland, G.L., Carter, R.H., and Kearney, J.F.
(1997a). Marginal zone B cells exhibit unique activation, proliferativeCzerny, T., Schaffner, G., and Busslinger, M. (1993). DNA sequence
and immunoglobulin secretory responses. Eur. J. Immunol. 27,recognition by Pax proteins: bipartite structure of the paired domain
2366–2374.and its binding site. Genes Dev. 7, 2048–2061.
Oliver, A.M., Martin, F., and Kearney, J.F. (1997b). Mouse CD38 isEberhard, D., Jime´nez, G., Heavey, B., and Busslinger, M. (2000).
down-regulated on germinal center B cells and mature plasma cells.Transcriptional repression by Pax5 (BSAP) through interaction with
J. Immunol. 158, 1108–1115.corepressors of the Groucho family. EMBO J. 19, 2292–2303.
Petrenko, O., Beavis, A., Klaine, M., Kittappa, R., Godin, I., andFu, C., Turck, C.W., Kurosaki, T., and Chan, A.C. (1998). BLNK: a
Lemischka, I.R. (1999). The molecular characterization of the fetalcentral linker protein in B cell activation. Immunity 9, 93–103.
stem cell marker AA4. Immunity 10, 691–700.Hayashi, K., Nittono, R., Okamoto, N., Tsuji, S., Hara, Y., Goitsuka,
Qiu, G., and Stavnezer, J. (1998). Overexpression of BSAP/Pax-5R., and Kitamura, D. (2000). The B cell-restricted adaptor BASH is
inhibits switching to IgA and enhances switching to IgE in the I.29	required for normal development and antigen receptor-mediated
B cell line. J. Immunol. 161, 2906–2918.activation of B cells. Proc. Natl. Acad. Sci. USA 97, 2755–2760.
Rickert, R.C., Rajewsky, K., and Roes, J. (1995). Impairment of T-cell-Hodgkin, P.D., Lee, J.-H., and Lyons, A.B. (1996). B cell differentia-
dependent B-cell responses and B-1 cell development in CD19-tion and isotype switching is related to division cycle number. J.
deficient mice. Nature 376, 352–355.Exp. Med. 184, 277–281.
Rickert, R.C., Roes, J., and Rajewsky, K. (1997). B lymphocyte-Jumaa, H., Wollscheid, B., Mitterer, M., Wienands, J., Reth, M.,
specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 25,and Nielsen, R.J. (1999). Abnormal development and function of B
1317–1318.lymphocytes in mice deficient for the signaling adaptor protein SLP-
65. Immunity 11, 547–554. Rinkenberger, J.L., Wallin, J.J., Johnson, K.W., and Koshland, M.E.
Immunity
790
(1996). An interleukin-2 signal relieves BSAP (Pax5)-mediated re-
pression of the immunoglobulin J chain gene. Immunity 5, 377–386.
Rolink, A.G., Andersson, J., and Melchers, F. (1998). Characteriza-
tion of immature B cells by a novel monoclonal antibody, by turnover
and by mitogen reactivity. Eur. J. Immunol. 28, 3738–3748.
Rolink, A.G., Nutt, S.L., Melchers, F., and Busslinger, M. (1999).
Long-term in vivo reconstitution of T-cell development by Pax5-
deficient B-cell progenitors. Nature 401, 603–606.
Roque, M.C., Smith, P.A., and Blasquez, V.C. (1996). A developmen-
tally modulated chromatin structure at the mouse immunoglobulin
 3 enhancer. Mol. Cell. Biol. 16, 3138–3155.
Sanderson, R.D., Lalor, P., and Bernfield, M. (1989). B lymphocytes
express and lose syndecan at specific stages of differentiation. Cell
Regul. 1, 27–35.
Schwenk, F., Sauer, B., Kukoc, N., Hoess, R., Mu¨ller, W., Kocks, C.,
Ku¨hn, R., and Rajewsky, K. (1997). Generation of Cre recombinase-
specific monoclonal antibodies, able to characterize the pattern of
Cre expression in cre-transgenic mouse strains. J. Immunol. Meth-
ods 207, 203–212.
Singh, M., and Birshtein, B.K. (1993). NF-HB (BSAP) is a repressor
of the murine immunoglobulin heavy-chain 3 enhancer at early
stages of B cell differentiation. Mol. Cell. Biol. 13, 3611–3622.
Steimle, V., Otten, L.A., Zufferey, M., and Mach, B. (1993). Comple-
mentation cloning of an MHC class II transactivator mutated in he-
reditary MHC class II deficiency (or bare lymphocyte syndrome).
Cell 75, 135–146.
Torres, R.M., Flaswinkel, H., Reth, M., and Rajewsky, K. (1996).
Aberrant B cell development and immune response in mice with a
compromised BCR complex. Science 272, 1804–1808.
Turner, C.A.J., Mack, D.H., and Davis, M.M. (1994). Blimp-1, a novel
zinc finger-containing protein that can drive the maturation of B
lymphocytes into immunoglobulin-secreting cells. Cell 77, 297–306.
Urba´nek, P., Wang, Z.-Q., Fetka, I., Wagner, E.F., and Busslinger,
M. (1994). Complete block of early B cell differentiation and altered
patterning of the posterior midbrain in mice lacking Pax5/BSAP.
Cell 79, 901–912.
Usui, T., Wakatsuki, Y., Matsunaga, Y., Kaneko, S., Koseki, H., and
Kita, T. (1997). Overexpression of B cell-specific activator protein
(BSAP/Pax-5) in a late B cell is sufficient to suppress differentiation
to an Ig high producer cell with plasma cell phenotype. J. Immunol.
158, 3197–3204.
Wakatsuki, Y.W., Neurath, M.F., Max, E.E., and Strober, W. (1994).
The B cell-specific transcription factor BSAP regulates B cell prolif-
eration. J. Exp. Med. 179, 1099–1108.
Wienands, J., Schweikert, J., Wollscheid, B., Jumaa, H., Nielsen,
P.J., and Reth, M. (1998). SLP-65: a new signaling component in B
lymphocytes which requires expression of the antigen receptor for
phosphorylation. J. Exp. Med. 188, 791–795.
Ying, H., Healy, J.I., Goodnow, C.C., and Parnes, J.R. (1998). Regula-
tion of mouse CD72 expression during B lymphocyte development.
J. Immunol. 161, 4760–4767.
